Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | September 30, 2026 | October 03, 2026 |
| ALIGN TECHNOLOGY INCALGN · Entity 3488 | Director | May 20, 2026 | May 22, 2026 |
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | March 06, 2023 | March 09, 2023 |
| American Exceptionalism Acquisition Corp. AAEXA · Entity 5376 | Director | September 25, 2025 | December 30, 2025 |
| SomaLogic, Inc.SLGCW · Entity 95310 | Director | September 01, 2021 | September 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 551 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 318 · Balance 551 F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
ALIGN TECHNOLOGY INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,553 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 3,553 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,836 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 1,836 · Balance 1,836 F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.
Adaptive Biotechnologies Corp
Report date March 06, 2023 · Filed March 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,968 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Grant · Acquired 14,775 · Balance 22,968 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06 | Direct | 23,329 |
Reported balance
After 2023-03-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-06 · Grant · Acquired 23,329 · Balance 23,329 F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.
American Exceptionalism Acquisition Corp. A
Report date September 25, 2025 · Filed December 30, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-09-25 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein.
SomaLogic, Inc.
Report date September 01, 2021 · Filed September 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-09-01 transaction · row 1
1 source rowRow 1 · 2021-09-01 · Other · Acquired 25,000 · Balance 25,000 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. |
| Warrants to purchase Class A Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01 | IndirectBy Conroy Family Foundation, Inc. | 166,666 |
Reported balance
After 2021-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-01 · Grant · Acquired 166,666 · Balance 166,666 F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-01 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA SCIENCES ACQUISITION CORP.
Report date July 01, 2020 · Filed July 07, 2020
Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Grant · Acquired 119,312 · Balance 1,397,738 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 1,397,738 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 29,061 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Grantor Retained Annuity Trust | 0 |
Reported balance
After 2026-03-23 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-03-23 · Disposition to issuer · Disposed 46,538 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Grantor Retained Annuity Trust | 0 |
Reported balance
After 2026-03-23 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-03-23 · Disposition to issuer · Disposed 86,750 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Grantor Retained Annuity Trust | 0 |
Reported balance
After 2026-03-23 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-03-23 · Disposition to issuer · Disposed 117,427 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.68 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-23 · Disposition to issuer · Disposed 235,388 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4: These options became exercisable in full on February 23, 2021. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-23 · Disposition to issuer · Disposed 66,047 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F8: These options became exercisable on February 27, 2022. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.62 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-23 · Disposition to issuer · Disposed 34,110 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F9: These options became exercisable on February 26, 2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-23 · Disposition to issuer · Disposed 100,916 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F10: These options became exercisable on February 14, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-23 · Disposition to issuer · Disposed 18,143 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F15: These RSUs vest in four equal annual installments beginning on February 28, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-23 · Disposition to issuer · Disposed 44,336 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F11: These RSUs vest in four equal annual installments beginning on February 28, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-23 · Disposition to issuer · Disposed 83,360 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F12: These RSUs vest in four equal annual installments beginning on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-23 · Disposition to issuer · Disposed 154,829 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F13: These RSUs vest in four equal annual installments beginning on February 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.
F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
F4: These options became exercisable in full on February 23, 2021.
F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
F8: These options became exercisable on February 27, 2022.
F9: These options became exercisable on February 26, 2023.
F10: These options became exercisable on February 14, 2024.
F11: These RSUs vest in four equal annual installments beginning on February 28, 2025.
F12: These RSUs vest in four equal annual installments beginning on February 27, 2026.
F13: These RSUs vest in four equal annual installments beginning on February 25, 2027.
F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
F15: These RSUs vest in four equal annual installments beginning on February 28, 2024.
Epizyme, Inc.
Report date August 12, 2022 · Filed August 16, 2022
Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-12 · Disposition to issuer · Disposed 53,324 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 28, 2019 20:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 20,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014801 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,025 Underlying: Common Stock · 20,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2016 that partially vested on February 26, 2019. The restricted stock units vest in four equal annual installments beginning on February 26, 2017. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2016 that partially vested on February 26, 2019. The restricted stock units vest in four equal annual installments beginning on February 26, 2017. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 20:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 20,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014801 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award on February 26, 2019. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 17:29 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 16,400 | $90.55 | $1,485,036.40 |
DisclosureSEC source: 0001209191-19-013638 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,936 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 23, 2019. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 995,038 shares, Mr. Conroy also holds, in the aggregate, an additional 1,143,183 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 17:29 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 34,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013638 · doc4.xml · derivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,650 Underlying: Common Stock · 34,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 23, 2017 that partially vested on February 23, 2019. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 23, 2017 that partially vested on February 23, 2019. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 17:29 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 34,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013638 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award on February 23, 2019. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 23,236 | $82.49 | $1,916,667.93 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · nonDerivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,011 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.32 to $82.48, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F8 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 976,787 shares, Mr. Conroy also holds, in the aggregate, an additional 1,177,508 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 181,250 | $81.90 | $14,844,193.75 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,247 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.33 to $82.31, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 36,453 | $80.78 | $2,944,782.70 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,090,497 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.32 to $81.29, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 28,605 | $79.89 | $2,285,339.27 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,950 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.32 to $81.31, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 34,853 | $78.80 | $2,746,416.40 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,555 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.32 to $79.25, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionPerformance Share Units · Derivative | 304,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · derivative · entry 9 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 304,397 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Performance Share Unit represents a contingent to receive one share of common stock. F10 · derivative.exercise_date: The PSU Award was subject to certain performance-based vesting requirements tied to the growth in the Company's stock price through the three-year period ending December 31, 2018 (the "Performance Period") as calculated by reference to the 20 trading day trailing average closing price of the Company's common stock (the "Stock Price") as of the last day of the Performance Period compared to such Stock Price as of the beginning of the Performance Period. The Stock Price as of the last day of the Performance Period was $67.25, representing a greater than 760% increase from the $8.85 Stock Price at the beginning of the Performance Period. At target, the PSU Award covered 202,931 PSUs. Because the Stock Price at the end of the Performance Period well exceeded the maximum target Stock Price, the reporting person earned the maximum number of PSUs to which he was entitled under the PSU Award. The PSUs vested on January 2, 2019 and settled into shares of Common Stock on January 24, 2019. F10 · derivative.expiration_date: The PSU Award was subject to certain performance-based vesting requirements tied to the growth in the Company's stock price through the three-year period ending December 31, 2018 (the "Performance Period") as calculated by reference to the 20 trading day trailing average closing price of the Company's common stock (the "Stock Price") as of the last day of the Performance Period compared to such Stock Price as of the beginning of the Performance Period. The Stock Price as of the last day of the Performance Period was $67.25, representing a greater than 760% increase from the $8.85 Stock Price at the beginning of the Performance Period. At target, the PSU Award covered 202,931 PSUs. Because the Stock Price at the end of the Performance Period well exceeded the maximum target Stock Price, the reporting person earned the maximum number of PSUs to which he was entitled under the PSU Award. The PSUs vested on January 2, 2019 and settled into shares of Common Stock on January 24, 2019. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 18:46 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 304,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005424 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,190,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received upon settlement of a performance share unit award (the "PSU Award") on January 23, 2019, which is described further in Footnote 5 to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:59 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantPerformance Share Units · Derivative | 304,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002061 · doc4.xml · derivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,397 Underlying: Common Stock · 304,397 shares Expires not disclosed F2 · security: Represents a PSU award granted on February 26, 2016 (the "PSU Award") which covered a three-year performance measurement period ending on December 31, 2018 (the "Performance Period") and was described in the Company's proxy statement filed with the Securities and Exchange Commission on April 28, 2017. F3 · derivative.exercise_price: Each Performance Share Unit represents a right to receive one share of common stock. F4 · derivative.exercise_date: The PSU Award was subject to certain performance-based vesting requirements tied to the growth in the Company's stock price through the end of the Performance Period as calculated by reference to the 20 trading day trailing average closing price of the Company's common stock (the "Stock Price") as of the last day of the Performance Period compared to such Stock Price as of the beginning of the Performance Period. The Stock Price as of the last day of the Performance Period was $67.25 representing a greater than 760% increase from the $8.85 Stock Price at the beginning of the Performance Period. At target, the PSU Award covered 202,931 PSUs. Because the Stock Price at the end of the Performance Period well exceeded the maximum target Stock Price, the reporting person earned the maximum number of PSUs to which he was entitled under the PSU Award. The PSUs are immediately vested and will settle into shares of Common Stock within 30 days from the date of issuance. F4 · derivative.expiration_date: The PSU Award was subject to certain performance-based vesting requirements tied to the growth in the Company's stock price through the end of the Performance Period as calculated by reference to the 20 trading day trailing average closing price of the Company's common stock (the "Stock Price") as of the last day of the Performance Period compared to such Stock Price as of the beginning of the Performance Period. The Stock Price as of the last day of the Performance Period was $67.25 representing a greater than 760% increase from the $8.85 Stock Price at the beginning of the Performance Period. At target, the PSU Award covered 202,931 PSUs. Because the Stock Price at the end of the Performance Period well exceeded the maximum target Stock Price, the reporting person earned the maximum number of PSUs to which he was entitled under the PSU Award. The PSUs are immediately vested and will settle into shares of Common Stock within 30 days from the date of issuance. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 163,514 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-18-058566 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,514 shares Expires 2019-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 163,514 | $69.00 | $11,282,466.00 |
DisclosureSEC source: 0001209191-18-058566 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,011 F3 · shares: The sales reported in this field were effected pursuant to a previously announced Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2018. F4 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 976,780 shares, Mr. Conroy also holds, in the aggregate, an additional 1,177,508 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 163,514 | $0.83 | $135,716.62 |
DisclosureSEC source: 0001209191-18-058566 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:34 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 2,878 | $13.55 | $38,996.90 |
DisclosureSEC source: 0001209191-18-040447 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,878 F1 · security: The shares were issued to the Reporting Person pursuant to his election under the Company's director compensation program in lieu of cash fees of $39,000 for Board services. Read SEC document |
| May 18, 2018 Filed May 31, 2018 20:23 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034359 · doc4.xml · derivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-17 F1 · derivative.exercise_date: This option was granted on May 18, 2018, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on May 18, 2019 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document |
| April 30, 2018 Filed Nov 14, 2018 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 3,572 | $5.95 | $21,253.40 |
DisclosureSEC source: 0001209191-18-058566 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,011 F1 · shares: Represents shares purchased through Employee Stock Purchase Plan. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 16:45 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 11,459 | $52.19 | $598,091.05 |
DisclosureSEC source: 0001209191-18-019251 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,439 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on March 9, 2018. F3 · balance_after: In addition to the shares of Common Stock and restricted stock units reported on this Form 4, which total 997,608 shares, Mr. Conroy also holds, in the aggregate, an additional 1,316,622 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 16:45 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 24,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019251 · doc4.xml · derivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on March 9, 2015 that partially vested on March 9, 2018. The restricted stock units vest in four equal annual installments beginning on March 9, 2016. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on March 9, 2015 that partially vested on March 9, 2018. The restricted stock units vest in four equal annual installments beginning on March 9, 2016. F3 · balance_after: In addition to the shares of Common Stock and restricted stock units reported on this Form 4, which total 997,608 shares, Mr. Conroy also holds, in the aggregate, an additional 1,316,622 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 16:45 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 24,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019251 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 16:44 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 82,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014532 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,300 Underlying: Common Stock · 82,300 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F7 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 16:44 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantStock Option (right to buy) · Derivative | 68,300 | $0.00 Strike: $44.37 | $0.00 |
DisclosureSEC source: 0001209191-18-014532 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,300 Underlying: Common Stock · 68,300 shares Expires 2028-02-27 F6 · derivative.exercise_date: These options vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 16:44 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 9,085 | $44.10 | $400,630.33 |
DisclosureSEC source: 0001209191-18-014532 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,498 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 26, 2018. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 960,267 shares, Mr. Conroy also holds, in the aggregate, an additional 1,365,422 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 18:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 25,319 | $42.34 | $1,071,955.82 |
DisclosureSEC source: 0001209191-18-014130 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858,558 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 23, 2018 and February 24, 2018. F3 · balance_after: In addition to the shares of Common Stock and restricted stock units reported on this Form 4, which total 1,052,302 shares, Mr. Conroy also holds, in the aggregate, an additional 1,131,872 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 16:44 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 20,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014532 · doc4.xml · derivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,050 Underlying: Common Stock · 20,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2016 that partially vested on February 26, 2018. The restricted stock units vest in four equal annual installments beginning on February 26, 2017. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2016 that partially vested on February 26, 2018. The restricted stock units vest in four equal annual installments beginning on February 26, 2017. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 16:44 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 20,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014532 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 24, 2018 Filed Feb 27, 2018 18:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014130 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 24, 2014 that partially vested on February 24, 2018. The restricted stock units vest in four equal annual installments beginning on February 24, 2015. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 24, 2014 that partially vested on February 24, 2018. The restricted stock units vest in four equal annual installments beginning on February 24, 2015. Read SEC document |
| February 24, 2018 Filed Feb 27, 2018 18:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014130 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 18:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 34,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014130 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,975 Underlying: Common Stock · 34,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 23, 2017 that partially vested on February 23, 2018. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 23, 2017 that partially vested on February 23, 2018. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. F3 · balance_after: In addition to the shares of Common Stock and restricted stock units reported on this Form 4, which total 1,052,302 shares, Mr. Conroy also holds, in the aggregate, an additional 1,131,872 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 18:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 34,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014130 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 101,488 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-18-009517 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,514 Underlying: Common Stock · 101,488 shares Expires 2019-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 9,458 | $46.29 | $437,839.19 |
DisclosureSEC source: 0001209191-18-009517 · doc4.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,052 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.10 to $46.65, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5 · balance_after: In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,083,755 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 50,504 | $46.54 | $2,350,456.16 |
DisclosureSEC source: 0001209191-18-009517 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,510 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.10 to $46.09, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 41,526 | $44.60 | $1,851,976.55 |
DisclosureSEC source: 0001209191-18-009517 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,014 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.10 to $45.09, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 101,488 | $0.83 | $84,235.04 |
DisclosureSEC source: 0001209191-18-009517 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 931,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: As previously announced by Exact Sciences Corporation in its Current Report on Form 8-K filed on August 11, 2017, the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017 which covers only the remaining portion of a stock option granted to Mr. Conroy in March 2009 that expires in March 2019. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 110,439 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-18-005361 · doc4.xml · derivative · entry 8 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,002 Underlying: Common Stock · 110,439 shares Expires 2019-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 30,036 | $51.66 | $1,551,659.76 |
DisclosureSEC source: 0001209191-18-005361 · doc4.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,052 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.17 to $52.09, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F6 · balance_after: In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,185,243 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 41,588 | $50.72 | $2,109,426.54 |
DisclosureSEC source: 0001209191-18-005361 · doc4.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860,088 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.16, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 26,738 | $49.54 | $1,324,707.47 |
DisclosureSEC source: 0001209191-18-005361 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,676 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.155 to $50.15, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 12,077 | $48.87 | $590,166.76 |
DisclosureSEC source: 0001209191-18-005361 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,414 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.15 to $49.145, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 110,439 | $0.83 | $91,664.37 |
DisclosureSEC source: 0001209191-18-005361 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: As previously announced by Exact Sciences Corporation in its Current Report on Form 8-K filed on August 11, 2017, the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017 which covers only the remaining portion of a stock option granted to Mr. Conroy in March 2009 that expires in March 2019. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 16:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 125,402 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-18-003924 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,441 Underlying: Common Stock · 125,402 shares Expires 2019-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,295,672 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 16:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 25,912 | $53.24 | $1,379,658.53 |
DisclosureSEC source: 0001209191-18-003924 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,052 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.13 to $53.44, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,295,672 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 16:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 99,490 | $52.68 | $5,240,934.22 |
DisclosureSEC source: 0001209191-18-003924 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,964 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.13 to $53.125, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 16:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 125,402 | $0.83 | $104,083.66 |
DisclosureSEC source: 0001209191-18-003924 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: As previously announced by Exact Sciences Corporation in its Current Report on Form 8-K filed on August 11, 2017, the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017 which covers only the remaining portion of a stock option granted to Mr. Conroy in March 2009 that expires in March 2019. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 16:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 123,512 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-17-067212 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,843 Underlying: Common Stock · 123,512 shares Expires 2019-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,421,074 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 16:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 27,065 | $53.36 | $1,444,053.08 |
DisclosureSEC source: 0001209191-17-067212 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,052 F1 · shares: As previously announced by Exact Sciences Corporation in its Current Report on Form 8-K filed on August 11, 2017, the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017 which covers only the remaining portion of a stock option granted to Mr. Conroy in March 2009 that expires in March 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.94 to $53.82, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,421,074 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 16:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 96,447 | $52.37 | $5,050,736.50 |
DisclosureSEC source: 0001209191-17-067212 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,117 F1 · shares: As previously announced by Exact Sciences Corporation in its Current Report on Form 8-K filed on August 11, 2017, the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017 which covers only the remaining portion of a stock option granted to Mr. Conroy in March 2009 that expires in March 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.93 to $52.92, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.